ID   SPRE_RAT                Reviewed;         262 AA.
AC   P18297;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   02-OCT-2024, entry version 165.
DE   RecName: Full=Sepiapterin reductase;
DE            Short=SPR;
DE            EC=1.1.1.153 {ECO:0000269|PubMed:10350607};
GN   Name=Spr;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=2201030; DOI=10.1073/pnas.87.16.6436;
RA   Citron B.A., Milstien S., Gutierrez J.C., Levine R.A., Yanak B.L.,
RA   Kaufman S.;
RT   "Isolation and expression of rat liver sepiapterin reductase cDNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:6436-6440(1990).
RN   [2]
RP   PROTEIN SEQUENCE, AND ACETYLATION AT MET-1.
RX   PubMed=2260974; DOI=10.1016/s0006-291x(05)80081-6;
RA   Oyama R., Katoh S., Sueoka T., Suzuki M., Ichinose H., Nagatsu T.,
RA   Titani K.;
RT   "The complete amino acid sequence of the mature form of rat sepiapterin
RT   reductase.";
RL   Biochem. Biophys. Res. Commun. 173:627-631(1990).
RN   [3]
RP   MUTAGENESIS OF ALA-29; SER-158; TYR-171 AND LYS-175, CATALYTIC ACTIVITY,
RP   AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10350607; DOI=10.1016/s0167-4838(99)00054-0;
RA   Fujimoto K., Ichinose H., Nagatsu T., Nonaka T., Mitsui Y., Katoh S.;
RT   "Functionally important residues tyrosine-171 and serine-158 in sepiapterin
RT   reductase.";
RL   Biochim. Biophys. Acta 1431:306-314(1999).
RN   [4]
RP   KINETIC PARAMETERS, PHOSPHORYLATION AT SER-46; SER-196 AND SER-214, AND
RP   MUTAGENESIS OF SER-46; SER-196 AND SER-214.
RX   PubMed=11825621; DOI=10.1016/s0167-4838(01)00300-4;
RA   Fujimoto K., Takahashi S.Y., Katoh S.;
RT   "Mutational analysis of sites in sepiapterin reductase phosphorylated by
RT   Ca2+/calmodulin-dependent protein kinase II.";
RL   Biochim. Biophys. Acta 1594:191-198(2002).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-33, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Catalyzes the final one or two reductions in tetra-
CC       hydrobiopterin biosynthesis to form 5,6,7,8-tetrahydrobiopterin.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-erythro-7,8-dihydrobiopterin + NADP(+) = H(+) + NADPH +
CC         sepiapterin; Xref=Rhea:RHEA:18953, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16095, ChEBI:CHEBI:43029, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; EC=1.1.1.153;
CC         Evidence={ECO:0000269|PubMed:10350607};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:18955;
CC         Evidence={ECO:0000269|PubMed:10350607};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin + 2 NADP(+) = 6-
CC         pyruvoyl-5,6,7,8-tetrahydropterin + 2 H(+) + 2 NADPH;
CC         Xref=Rhea:RHEA:32627, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:59560, ChEBI:CHEBI:136564;
CC         EC=1.1.1.153; Evidence={ECO:0000305|PubMed:10350607};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:32629;
CC         Evidence={ECO:0000305|PubMed:10350607};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=12.6 uM for sepiapterin {ECO:0000269|PubMed:10350607,
CC         ECO:0000269|PubMed:11825621};
CC         KM=2.8 uM for NADPH {ECO:0000269|PubMed:10350607,
CC         ECO:0000269|PubMed:11825621};
CC         Note=kcat is 9.7 sec(-1) with sepiapterin as substrate
CC         (PubMed:10350607). kcat is 11.1 sec(-1) with NADPH as substrate
CC         (PubMed:10350607). {ECO:0000269|PubMed:10350607};
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- PTM: In vitro phosphorylation of Ser-46, Ser-196 and Ser-214 by CaMK2
CC       does not change kinetic parameters. {ECO:0000269|PubMed:11825621}.
CC   -!- SIMILARITY: Belongs to the sepiapterin reductase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M36410; AAA42130.1; -; mRNA.
DR   PIR; A36024; A36024.
DR   RefSeq; NP_062054.1; NM_019181.1.
DR   AlphaFoldDB; P18297; -.
DR   SMR; P18297; -.
DR   STRING; 10116.ENSRNOP00000020749; -.
DR   iPTMnet; P18297; -.
DR   PhosphoSitePlus; P18297; -.
DR   jPOST; P18297; -.
DR   PaxDb; 10116-ENSRNOP00000020749; -.
DR   Ensembl; ENSRNOT00000020749.7; ENSRNOP00000020749.4; ENSRNOG00000015455.7.
DR   Ensembl; ENSRNOT00055022005; ENSRNOP00055017847; ENSRNOG00055012862.
DR   Ensembl; ENSRNOT00060042333; ENSRNOP00060035093; ENSRNOG00060024409.
DR   Ensembl; ENSRNOT00065027685; ENSRNOP00065021806; ENSRNOG00065016616.
DR   GeneID; 29270; -.
DR   KEGG; rno:29270; -.
DR   UCSC; RGD:3753; rat.
DR   AGR; RGD:3753; -.
DR   CTD; 6697; -.
DR   RGD; 3753; Spr.
DR   eggNOG; KOG1204; Eukaryota.
DR   GeneTree; ENSGT00440000033609; -.
DR   HOGENOM; CLU_010194_2_11_1; -.
DR   InParanoid; P18297; -.
DR   OMA; DMFTRTF; -.
DR   OrthoDB; 64672at2759; -.
DR   PhylomeDB; P18297; -.
DR   TreeFam; TF326358; -.
DR   BRENDA; 1.1.1.153; 5301.
DR   Reactome; R-RNO-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   Reactome; R-RNO-203615; eNOS activation.
DR   SABIO-RK; P18297; -.
DR   PRO; PR:P18297; -.
DR   Proteomes; UP000002494; Chromosome 4.
DR   Bgee; ENSRNOG00000015455; Expressed in liver and 19 other cell types or tissues.
DR   ExpressionAtlas; P18297; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0004757; F:sepiapterin reductase (NADP+) activity; IDA:UniProtKB.
DR   GO; GO:0048667; P:cell morphogenesis involved in neuron differentiation; ISO:RGD.
DR   GO; GO:0042417; P:dopamine metabolic process; ISO:RGD.
DR   GO; GO:0006558; P:L-phenylalanine metabolic process; ISO:RGD.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; ISO:RGD.
DR   GO; GO:0042415; P:norepinephrine metabolic process; ISO:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:RGD.
DR   GO; GO:0019889; P:pteridine metabolic process; ISO:RGD.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISO:RGD.
DR   GO; GO:0042428; P:serotonin metabolic process; ISO:RGD.
DR   GO; GO:0006729; P:tetrahydrobiopterin biosynthetic process; IMP:RGD.
DR   GO; GO:0046146; P:tetrahydrobiopterin metabolic process; ISO:RGD.
DR   GO; GO:0050882; P:voluntary musculoskeletal movement; ISO:RGD.
DR   CDD; cd05367; SPR-like_SDR_c; 1.
DR   Gene3D; 3.40.50.720; NAD(P)-binding Rossmann-like Domain; 1.
DR   InterPro; IPR051721; Biopterin_syn/organic_redct.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR002347; SDR_fam.
DR   InterPro; IPR006393; Sepiapterin_red.
DR   NCBIfam; TIGR01500; sepiapter_red; 1.
DR   PANTHER; PTHR44085; SEPIAPTERIN REDUCTASE; 1.
DR   PANTHER; PTHR44085:SF2; SEPIAPTERIN REDUCTASE; 1.
DR   Pfam; PF00106; adh_short; 1.
DR   PRINTS; PR00081; GDHRDH.
DR   SUPFAM; SSF51735; NAD(P)-binding Rossmann-fold domains; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Cytoplasm; Direct protein sequencing; NADP; Oxidoreductase;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN           1..262
FT                   /note="Sepiapterin reductase"
FT                   /id="PRO_0000072151"
FT   BINDING         15..21
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250"
FT   BINDING         43..44
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250"
FT   BINDING         70..71
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250"
FT   BINDING         158..159
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         171
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         175
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250"
FT   BINDING         200
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         202..207
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000250"
FT   BINDING         258
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|PubMed:2260974"
FT   MOD_RES         33
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         46
FT                   /note="Phosphoserine; by CaMK2; in vitro"
FT                   /evidence="ECO:0000269|PubMed:11825621"
FT   MOD_RES         196
FT                   /note="Phosphoserine; by CaMK2; in vitro"
FT                   /evidence="ECO:0000269|PubMed:11825621"
FT   MOD_RES         214
FT                   /note="Phosphoserine; by CaMK2; in vitro"
FT                   /evidence="ECO:0000269|PubMed:11825621"
FT   MUTAGEN         29
FT                   /note="A->V: Reduces affinity for NADP and for sepiapterin
FT                   4-fold."
FT                   /evidence="ECO:0000269|PubMed:10350607"
FT   MUTAGEN         46
FT                   /note="S->A: Abolishes phosphorylation by CaMK2. No effect
FT                   on kinetic parameters; when associated with A-196 and A-
FT                   214."
FT                   /evidence="ECO:0000269|PubMed:11825621"
FT   MUTAGEN         158
FT                   /note="S->D: Reduces activity 4-fold. Loss of activity;
FT                   when associated with V-171."
FT                   /evidence="ECO:0000269|PubMed:10350607"
FT   MUTAGEN         171
FT                   /note="Y->V: Reduces activity 4-fold. Loss of activity;
FT                   when associated with V-171."
FT                   /evidence="ECO:0000269|PubMed:10350607"
FT   MUTAGEN         175
FT                   /note="K->I: Reduces activity 4-fold."
FT                   /evidence="ECO:0000269|PubMed:10350607"
FT   MUTAGEN         196
FT                   /note="S->A: Abolishes phosphorylation by CaMK2. No effect
FT                   on kinetic parameters; when associated with A-46 and A-
FT                   214."
FT                   /evidence="ECO:0000269|PubMed:11825621"
FT   MUTAGEN         214
FT                   /note="S->A: Abolishes phosphorylation by CaMK2. No effect
FT                   on kinetic parameters; when associated with A-46 and A-
FT                   196."
FT                   /evidence="ECO:0000269|PubMed:11825621"
SQ   SEQUENCE   262 AA;  28128 MW;  EC992564A0334C61 CRC64;
     MEGGRLGCAV CVLTGASRGF GRALAPQLAG LLSPGSVLLL SARSDSMLRQ LKEELCTQQP
     GLQVVLAAAD LGTESGVQQL LSAVRELPRP ERLQRLLLIN NAGTLGDVSK GFLNINDLAE
     VNNYWALNLT SMLCLTTGTL NAFSNSPGLS KTVVNISSLC ALQPFKGWGL YCAGKAARDM
     LYQVLAVEEP SVRVLSYAPG PLDTNMQQLA RETSMDPELR SRLQKLNSEG ELVDCGTSAQ
     KLLSLLQRDT FQSGAHVDFY DI
//
